AUTL

In a report released today, Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics (AUTL - Research Report), with a price target of $7.00. The company's shares closed yesterday at $2.99.According to TipRanks, Blum is an analyst with an average return of -25.5% and a 24.62% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rocket Pharmaceuticals, and G1 Therapeutics.Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $11.00, which is a 267.89% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $18.
https://www.tipranks.com/news/blurbs/needham-remains-a-buy-on-autolus-therapeutics-autl-2?utm_source=advfn.com&utm_medium=referral